Sanofi Spotlights Nirsevimab In RSV, Further Dupixent Development
Oncology Sales Growing
Sanofi executives are upbeat about the potential advantages of its monoclonal antibody-based approach to the prevention of RSV infections in infants, the future growth of the company’s Dupixent franchise, and the progress of its novel anticancers.
